Pfizer Vfend approval
Executive Summary
Pfizer's Vfend receives supplemental approval for treatment of esophageal candidiasis Nov. 14. Vfend (voriconazole) was initially approved for primary invasive aspergillosis therapy in May 2002 (1"The Pink Sheet" June 3, 2002, p. 10)...
You may also be interested in...
Vfend dosing options expand
Oral suspension form of Pfizer's antifungal Vfend (voriconazole) receives FDA nod Dec. 9. Approval letter says Pfizer will conduct a "two-way drug interaction study between voriconazole and oral contraceptives." Dosage form joins tablets and injection (1"The Pink Sheet" Nov. 24, 2003, In Brief)...
Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas
Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.